跳至主要内容
临床试验/CTRI/2013/12/004253
CTRI/2013/12/004253招募中3 期

EVALUATION OF SAFETY AND EFFICACY OF A POLY HERBAL FORMULATION ADATHODAI CHOORANAM IN IYA ERAIPPU NOI(BRONCHIAL ASTHMA)

AYOTHIDOSS PANDITHAR HOSPITAL1 个研究点 分布在 1 个国家目标入组 125 人开始时间: 2013年12月15日最近更新:

试验速览

阶段
3 期
状态
招募中
发起方
入组人数
125
试验地点
1
主要终点
Moderate response

研究概览

简要总结

It is a single, non-randomized, open-label trial to determine the efficacy and safety of ADATHODAI CHOORANAM in patients with IYA ERAIPPU NOI (BRONCHIAL ASTHMA). The trial drug Adathodai Chooranam is a herbal formulation taken from the classical Siddha text Book ‘Sigitcha Rathna Deepam Enum Vaidhya Nool’ Page No.118 & 119 which is a approved text Book of Drug and Cosmetics Act 1940.In this trial 125 Bronchial asthma patients will be recruited and the trial drug  will be administered 1.5 gm twice a day along with milk  for a period of 30 days. During this trial period all the study related data will be recorded and documented in a separate trial master file for each patients.During the trial period if any AE/SAE/SUSAR will be noticed and referred to pharmacovigilance dept.in NIS and further management will also be given in NIS OPD/IPD. The entire trial will be monitored by the research monitoring committee OF NIS. During this trial all the safety and efficacy parameters will be recorded in the CRF. After completion of the trial all the study related data will be analysed statistically .The out come of this trial will be published in Indian Journal of Medical Research.

研究设计

研究类型
Interventional
分配方式
Not Applicable
盲法
Open Label

入排标准

年龄范围
15.00 Year(s) 至 60.00 Year(s)(—)
性别
All

入选标准

  • 1.Patients who are having classical symptoms of Bronchial Asthma that difficulty in breathing, Tightness of Chest, Wheezing, Dry (or) Productive Cough, 2.Only new patients will be included.
  • 3.Aged between 15 to 60 years of both sexes.
  • 4.Willing to give blood specimen, sputum, Radiological Investigation and Willing to be admitted in the hospital (or) attend the OPD once a week for 3 weeks.
  • 5.Patients who are willing to estimate volume of air forcibly expired after a deep inspiration by using peak flow meter.

排除标准

  • 1.Pregnancy and Lactation period.
  • 2.Significant Systemic illness including Cardiac Diseases, Renal Diseases, Hypertension.
  • 3.Patients with only nasal block or rhinorrhoea.
  • 4.Other respiratory Diseases such as Tuberculosis, Pneumonia, COPD,Bronchiectasis, cystic fibroisis, 5.Endocrine Disorders like Hypo & Hyper Thyroidism, Diabetes Mellitus 6.Status Asthmaticus.

结局指标

主要结局

Moderate response

时间窗: PRE STUDY SCREENING AND AFTER 30 DAYS OF TREATMENT

Poor response

时间窗: PRE STUDY SCREENING AND AFTER 30 DAYS OF TREATMENT

Outcome

时间窗: PRE STUDY SCREENING AND AFTER 30 DAYS OF TREATMENT

Step3Step1/Step2/Normal

时间窗: PRE STUDY SCREENING AND AFTER 30 DAYS OF TREATMENT

PEEK EXPIRATORY FLOW MEASUREMENT

时间窗: PRE STUDY SCREENING AND AFTER 30 DAYS OF TREATMENT

Good response

时间窗: PRE STUDY SCREENING AND AFTER 30 DAYS OF TREATMENT

Step4 Step1/Step2/Normal

时间窗: PRE STUDY SCREENING AND AFTER 30 DAYS OF TREATMENT

Step4 to Step3

时间窗: PRE STUDY SCREENING AND AFTER 30 DAYS OF TREATMENT

no Significant

时间窗: PRE STUDY SCREENING AND AFTER 30 DAYS OF TREATMENT

次要结局

  • Eosinophils and ESR,(AEC, Serum IgE level)

研究者

发起方
AYOTHIDOSS PANDITHAR HOSPITAL
申办方类型
Research institution and hospital

研究点 (1)

Loading locations...

相似试验